APYX Medical study shows Renuvion improves liposuction outcomes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction
May 14, 2026 8:00 AM EDTCLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (the Company or Apyx Medical), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System (AYON), today announced the publication of a new retrospective investigator-initiated study in Plastic and Reconstructive Surgery - Global Open1. The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency (Renuvion).
The results demonstrate that... More
